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An important contribution of the thalamus to the transition from wakefulness to sleep
is a consistent finding in animal studies. In humans, only little is currently known about
the specific role of the thalamus in regulating wake-sleep transitions. Although changes
in thalamic blood flow and activity have been reported, the underlying molecular
mechanisms have not been investigated. Knowledge about neurotransmitter changes
at the wake-to-sleep transition would be indispensable for a better translation of basic
animal research findings to humans. Here, we start to fill this important scientific
gap. More specifically, we benefit from recent advances in magnetic resonance (MR)
spectroscopy, which allow for the non-invasive, local-specific and high-quality detection
of naturally occurring metabolite changes in the human brain. We demonstrate in nine
young adults able to produce consolidated sleep in the MR spectroscopy scanner,
a specific decrease in thalamic glutamate concentration from wakefulness to stage
N2 sleep. The magnitude of this decrease was highly correlated with individual N2
sleep duration. When five participants of the original experiment were kept awake
in a separate control condition, no decrease in thalamic glutamate levels occurred.
The study highlights for the first time in humans that dynamic changes in distinct
brain metabolites can be reliably detected at the transition from waking to sleep.
The reported methodology to simultaneously acquire functional MR spectroscopy data
and neurophysiological signals offers great potential for investigating the molecular
mechanisms underlying the transition between and the maintenance of sleep and wake
states in humans.
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INTRODUCTION
Brain neuronal activity and metabolism are fundamentally
different in wakefulness and sleep, particularly in thalamic and
cortical networks (for reviews, see e.g., McCormick and Bal,
1997; Vantomme et al., 2019). The electroencephalogram (EEG)
in deep non-rapid-eye-movement (NREM) sleep shows a high
prevalence of slow waves, which can be quantified by power
spectral analysis as slow-wave activity. EEG slow-wave activity (∼
0.75–4.5 Hz) includes the slow oscillation (<∼1.5 Hz), reflecting
widespread cortical alternations between neuronal UP (ON)
and DOWN (OFF) periods (Vyazovskiy et al., 2009; Nir et al.,
2011), and delta waves (>∼1.5 Hz) that are widely accepted
as a homeostatically regulated physiological marker of sleep
depth (Achermann and Borbély, 2017). The thalamus and the
surrounding thalamic reticular nucleus are thought to make
strong contributions to the generation mechanisms of the slow
oscillation, delta waves and sleep spindles, which are the EEG
hallmarks of NREM sleep in animals and humans (Crunelli et al.,
2018; Vantomme et al., 2019).
Consistent with this notion, early positron emission
tomography studies in humans revealed that the strongest
reduction in regional cerebral blood flow (rCBF) occurred in the
thalamus when slow wave sleep was compared to wakefulness
(Maquet et al., 1997). Moreover, the changes in rCBF were
correlated with EEG delta and spindle (12–15 Hz) frequency
activity in NREM sleep (Hofle et al., 1997). More recent
functional magnetic resonance imaging (MRI) studies confirmed
decreased thalamic activity inferred from arterial spin labeling
in NREM sleep when compared to waking (Tüshaus et al.,
2017). Intriguingly, simultaneous intracortical and intrathalamic
EEG recordings in human epileptic patients demonstrated that
the thalamic deactivation occurring at sleep onset typically
precedes that of the cortex by several minutes (Magnin et al.,
2010). Together with preclinical insights from correlational,
lesion/ablation, pharmacological and genetic studies, the
available evidence is consistent with an important role of the
thalamus for the occurrence of NREM sleep oscillations in
the cortex, but also for the transition from wakefulness to
sleep (David et al., 2013; Hughes and Crunelli, 2013; Lemieux
et al., 2014; Gent et al., 2018a). Nevertheless, the molecular
mechanisms controlling the thalamic neuronal firing patterns in
wake and sleep states are virtually unknown.
Earlier neurochemical models of brain circuits controlling
wakefulness and sleep primarily proposed monoaminergic and
cholinergic mechanisms originating in hypothalamus and basal
forebrain (Saper et al., 2010; Brown et al., 2012). More recently, it
has been argued that these classic neuromodulators merely play
a modulatory role, whereas fast acting neurotransmitters such
as glutamate (GLU) and γ-aminobutyric acid (GABA) provide
the main grid of the wake-sleep regulatory systems (Saper and
Fuller, 2017). Indeed, it has long been proposed that a decrease
in GLU and an increase in GABA function are fundamental
for sleep-related behaviors (for an overview, see Jones, 2011).
Interestingly, modafinil, a wake-promoting agent, increases GLU
in thalamic areas (Ferraro et al., 1997). While subregions of the
thalamus have emerged as essential hubs for controlling cortical
activity and behavioral state (Giber et al., 2015; Liu et al., 2015;
Gent et al., 2018b), the exact roles of GLU and GABA, the
main excitatory and inhibitory neurotransmitters, in sleep-wake
regulation remain unclear.
Knowledge about dynamic changes in these neurotransmitter
systems in humans at the wake-to-sleep transition is currently
lacking. To start filling this scientific gap, we used recent
methodological advances that allow for the non-invasive
detection of naturally occurring metabolite concentrations with
high data quality in circumscribed areas of the human brain. We
acquired functional MR spectroscopy data with high temporal
resolution simultaneously with polysomnography, to objectively
define the wake-to-sleep transition in healthy adults. Based on
previous data in rats (Dash et al., 2009), we hypothesized that the
GLU level in the thalamus would decrease from wakefulness to
sleep and that the magnitude of this decrease may be associated
with the depth of sleep.
MATERIALS AND METHODS
Participants
Fifteen adults between 19 and 24 years of age were recruited
via advertisements at the University of Zurich. All participants
had previous experience with MR studies, were familiar with
staying in the scanner for more than 45 min and sleeping
on their back in the constrained scanner environment. None
fulfilled any of the following exclusion criteria: history of
psychiatric/neurological diseases, sleep-wake abnormalities, drug
abuse, concurrent medication use, cardiovascular disease, MR
exclusion criteria, and pregnancy. No traveling across time zones
was allowed for at least 6 weeks before the study. Subjects had
to refrain from alcohol, caffeine and sports activities during 24 h
prior to the experiment. The Ethics Committee of the Canton of
Zurich approved the study. All subjects gave written informed
consent before screening.
Experimental Procedure
One week prior to the experimental night, participants were
instructed to keep a regular sleep-wake schedule according
to their individual habitual sleep-wake times. Compliance was
verified with self-reported sleep logs and wrist motor actigraphy
and light sensors (MotionWatch 8, CamNtech Ltd., Cambridge,
United Kingdom). In the night prior to the assessment, the
subjects’ average sleep duration across the pre-study week was
reduced by 2 h to slightly elevate sleep pressure. Actigraphic data
were controlled at the beginning of each experimental session, to
ensure compliance with the study instructions.
On the night of the MR spectroscopy and sleep recordings,
subjects arrived ∼ 3 h before their usual bedtime at the MR
center of the Psychiatric Hospital Zürich for the application
of the electrodes for polysomnography. The experimental set-
up included 32 EEG channels according to an extended
10–20 system (Brain Products GmbH, Gilching, Germany),
electrooculogram (EOG), submental electromyogram (EMG),
and electrocardiogram (ECG). The MR protocol started with a
structural MRI scan around 2 h before the subjects’ habitual
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bedtime, to avoid sleepiness in the scanner. Participants were
asked to stay awake for at least 20 min during initial
MR spectroscopy scanning, to collect sufficient data during
wakefulness. Afterward, they were permitted to sleep. The
MR spectroscopy and polysomnographic measurements were
continued for as long as the volunteers were able to remain in
the MR scanner without gross movements. Six study participants
were unable to sleep (n = 2) or slept for less than 15 min
(n = 4). They were excluded from data analyses, resulting in a
final study sample of five females and four males (mean age:
22.3± 2.2 [SEM] years).
To control for diurnal or non-sleep-related temporal changes
in metabolite ratios during the prolonged measurement period,
all participants who were able to sleep in the scanner for longer
than 15 min in sleep stages N2 and N3 were invited for a second
recording. This additional experimental condition followed the
same procedures as described above, yet the volunteers were
required to stay awake as controlled by polysomnography for the
entire duration of MR spectroscopy scanning.
MR Spectroscopy Data Acquisition
1H-MR spectroscopy measurements were performed on a Philips
Achieva 3T whole-body scanner equipped with a 32-channel
receive-only phased-array head coil (Philips Healthcare, Best,
The Netherlands). Non-water suppressed, PRESS-localized 1H-
MR spectroscopy spectra in the thalamus (Figure 1A) were
obtained using the metabolite cycling (MC) technique (Hock
et al., 2013). This technique allows for the correction of frequency
and phase changes caused by system instabilities (e.g., B0-field
drifts, blood or cerebrospinal fluid flow, patient movements)
between each single acquisition. In addition, this method enables
a flexible selection of acquisitions from different time points
for a retrospective averaging within the scan session based on
the sleep states defined by the polysomnographic analyses. The
PRESS localization sequence parameters were chosen as follows:
2500 ms repetition time, 32 ms echo time and 2000 Hz spectral
bandwidth and was combined with inner-volume saturation
(Edden et al., 2006).
Polysomnographic Recording During MR
Spectroscopy Scanning and Artifact
Correction
Wakefulness and sleep during scanning were confirmed by
polysomnography as described above using an MR-compatible
polysomnographic recording system (BrainAmp, BrainCap and
BrainAmp ExG MR devices and electrodes; Brain Products
GmbH, Gilching, Germany). Impedances of all electrodes were
kept below 10 k. The bioelectric data were synchronized with
the scanner clock, sampled at 5 kHz (filtered between 0.01 and
200 Hz) and referenced to the vertex (Cz).
Sleep EEG Correction and Sleep-State
Scoring
Oﬄine EEG data correction was performed using BrainVision
Analyzer 2.0 (Brain Products, Gilching, Germany). Removal
of MR spectroscopy artifacts was based on the average
artifact subtraction method, whereas 21 MR spectroscopy
artifact intervals were used for sliding average (Allen et al.,
2000). Subsequently, data were corrected with a standard
cardioballistogram (CB) artifact template correction (Allen et al.,
1998). The cardioballistic artifact template was determined from
the cardiac waveform recorded by the ECG channel. The CB
artifact to be subtracted was defined by a moving average over 21
cardiac periods. Both, CB and MR artifact correction routines are
pre-implemented in the software. The EEG data were high-pass
filtered at 0.3 Hz and low-pass filtered at 35 Hz (48 dB/octave)
and subsequently down-sampled to 512 Hz for the scoring of
waking and sleep states. After MR spectroscopy and CB artifact
correction, the polysomnographic recordings were scored oﬄine
in 30-s epochs by two independent raters according to standard
criteria (Iber et al., 2007).
MR Spectroscopy Analyses
Each single MR spectroscopy acquisitions was phase corrected
and frequency aligned exploiting the advantages of the non-
water suppressed acquisition scheme before acquisitions scored
as the same sleep state were averaged. After averaging,
eddy-current correction (Klose, 1990) was applied using
the unsuppressed water signal to reduce induced line-shape
distortions. Additionally, a Hankel singular value decomposition
water filter was applied to remove the remaining water peak in
the resulting metabolite spectrum (Cabanes et al., 2001).
For quantification of spectral data, LCModel (Version 6.3)
with a set of simulated basis spectra, consisting of 18 metabolites,
was used (Provencher, 1993). For each metabolite, the ratio to the
unsuppressed water signal was calculated.
Based on the polysomnographic recordings, single MR
acquisitions were classified into wakefulness and NREM stages,
N1, N2, and N3. Signal-to-noise-ratio (SNR) and full-width-
at-half-maximum of the spectra according to the LCModel
output were compared between categories (i.e., wakefulness
and sleep states).
Statistical Analyses
Metabolic ratios between wakefulness and sleep were compared
using paired t-tests. The relationship between sleep variables
and changes in metabolic ratios were analyzed using Pearson’s
product-moment correlation coefficients. A Bonferroni-
corrected probability of p = 0.05 was set as the significance
threshold, yet the uncorrected p-values are reported.
RESULTS
Actigraphic data to control the pre-experimental study
instructions were verified at the beginning of each
experimental night.
The “sleep” experiment started at 9.56 pm ± 56 min.
Following the pre-sleep wake scan and once permitted
to fall asleep, the participants took on average 10.3 min
(SD = 7.4 min) to produce N2 sleep and maintained
79.7 min (SD = 20.8 min) of sleep in the scanner (range:
37 - 115 min). Sleep was composed of roughly 20%
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FIGURE 1 | Changes in water-scaled glutamate (GLU) ratios from wakefulness to N2 sleep. (A) MR spectroscopy voxel placement in the thalamus. (B) GLU levels
decreased from wakefulness to sleep in 8 of 9 study participants (arbitrary units; p < 0.01, two-tailed, paired t-tests) (C) The change from wakefulness to sleep was
negatively correlated with N2 sleep duration. Individual participant’s data have the same color code in panels (B,C). (D) When a subset of participants stayed awake
during an equivalent recording period at the same time of day, no changes in GLU were observed. No changes were observed in GABA ratios, neither from
wakefulness to sleep (E) nor during the wake control condition (F). Each individual participant’s data have the same color code in panels (B–F).
N3, 57% N2 and 13% N1 sleep, while wakefulness after
sleep onset equaled approximately 10% (Table 1). No
REM sleep occurred.
Analyses of the metabolite changes indicated that the SNR
differed significantly between waking and sleep, when “N3” sleep
was included in the category “sleep” (t8 = 7.20, p < 0.001,
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TABLE 1 | Visually scored sleep variables.
Sleep variable Duration (min) Percentage of TST (%)
Wakefulness before sleep 29.1 ± 8.4 n/a
Sleep latency 10.3 ± 7.4 n/a
Total sleep time (TST) 79.7 ± 20.8 n/a
N1 sleep 9.1 ± 5.6 12.8 ± 9.0
N2 sleep 45.4 ± 15.5 57.3 ± 14.4
N3 sleep 18.2 ± 17.5 20.6 ± 14.9
REM sleep 0.0 ± 0.0 0.0 ± 0.0
WASO 7.0 ± 5.2 9.4 ± 6.6
Mean values ± SD are reported (n = 9). Sleep latency: time after permission to fall
asleep until first occurrence of N2 sleep, defining sleep onset. REM sleep, rapid-
eye-movement sleep; WASO, wakefulness after sleep onset.
TABLE 2 | Water-scaled metabolite concentrations in wakefulness before sleep
and during sleep.
Metabolite Wakefulness Sleep t-value p-value
Glutamate 30.1 ± 2.2 27.4 ± 2.6 −3.74 0.006
Glutamine 6.6 ± 3.0 7.4 ± 3.2 0.82 0.44
Glutamate + glutamine 36.7 ± 3.9 34.8 ± 4.5 −1.76 0.12
γ-Aminobutyric acid 5.8 ± 1.4 6.5 ± 1.7 1.74 0.12
Aspartate 6.1 ± 1.5 5.2 ± 1.9 −1.71 0.31
N-acetyl-aspartate 39.1 ± 2.5 38.8 ± 3.1 −0.51 0.62
Myoinositol 16.1 ± 1.3 16.2 ± 2.0 0.25 0.81
Glutathione 2.2 ± 0.6 2.2 ± 0.7 −0.10 0.92
Mean values ± SD in arbitrary units are reported (n = 9). t- and p-values refer to
two-sided, paired t-tests.
d = 1.01). This rendered the metabolite ratios non-comparable
between wakefulness and sleep. The SNR did not differ when
ratios were compared between wakefulness and N2 sleep
(t8 = 0.68, p = 0.541).
In all participants but one, the thalamic GLU concentration
decreased from wakefulness to N2 sleep (t8 = −3.74, p = 0.006,
d = 1.25; Figure 1B). During the 2-h recording period, the
decrease in GLU was tightly inversely correlated with the
duration of N2 sleep (r = −0.84; p = 0.005; Figure 1C).
Interestingly, the single subject not showing a reduction in
thalamic GLU levels, only produced 17 min of N2 sleep in the MR
scanner (Figure 1C; “red” participant). Apart from GLU, no other
metabolite, including GABA (Figure 1E), showed a difference
between wakefulness and sleep (p> 0.117; Table 2).
To determine whether the observed changes in thalamic
GLU concentration were sleep related or merely reflected
diurnal or temporal changes in metabolite ratios, seven
participants of the “sleep” experiment completed a control
recording at the same time of day, but in the absence of
sleep. The presence of wakefulness during the entire duration
of functional MR spectroscopy scanning was controlled by
polysomnography. Five volunteers were able to stay awake
during the entire control measurement (89.3 ± 21.5 min).
Confirming that sleep is required for the observed decrease
in GLU at the sleep-to-wake transition, no reliable changes in
GLU (Figure 1D) nor in any other metabolite ratio [including
GABA (Figure 1F); other data not shown] were observed when
subjects stayed awake.
DISCUSSION
The present study provides first experimental evidence for
dynamic changes in thalamic GLU concentration at the
transition from wakefulness to sleep in humans. The unique
data set required the ability to average individual functional
MR spectroscopy acquisitions based on the polysomnography-
defined occurrence of wakefulness and sleep states. These
methodological innovation enabled the reliable quantification of
minute metabolic changes in the glutamatergic system between
wakefulness and sleep.
At the transition from waking to sleep, a specific decrease in
GLU was observed whereas other metabolites did not change.
This suggests that our finding is not biased by a general reduction
in the water signal, which was used for the scaling of the
metabolite values. Moreover, the decrease in GLU was stronger in
participants reaching more stable NREM sleep. This observation
is in line with previous observations in rat cerebral cortex
showing that the rate of decrease in GLU varies with sleep depth
and increases when animals are awake (Dash et al., 2009). The
latter indicates that changes in glutamatergic metabolism are
not mainly driven by circadian mechanisms. Of note, Dash and
colleagues studied sleep-wake related and diurnal changes in
GLU in rats and their findings may not be transferred directly
to humans. In the present study, a circadian contribution to
the level of GLU in the human thalamus was not assessed.
Moreover, while the removal of scanner artifacts from the EEG
allowed the reliable scoring of wakefulness and sleep states, a
reliable quantitative analysis of the EEG signals was not possible.
Nevertheless, the wake control experiment corroborated the
observation in rats that the cerebral GLU levels do not decrease
in reliable manner in the absence of sleep. Substantial preclinical
evidence supports important roles of thalamic neurons and
thalamo-cortical networks in EEG NREM sleep oscillations and
the control of behavioral states (wake vs. sleep) (Crunelli et al.,
2018; Gent et al., 2018b; Vantomme et al., 2019). The present
human data are consistent with the hypothesis that an elevated
thalamic GLU concentration promotes the tonic, single-spike
activity of thalamo-cortical neurons and the thalamic reticular
nucleus typical for wakefulness, whereas reduced thalamic GLU
levels facilitate the occurrence of EEG NREM sleep oscillations
and consolidated sleep. This conclusion may also be consistent
with computational modeling (Destexhe et al., 1994) and in vitro
slice electrophysiology data (Cox and Sherman, 1999).
Even though 6 out of 9 participants showed an increase
in GABA concentration from wakefulness to sleep, the change
was not significant. The reliable detection of GABA with MR
spectroscopy in small voxels is generally difficult because of
the relatively low abundance of GABA and the spectral overlap
with signals from more abundant metabolites. We found no
correlation between the wake-sleep related changes in GLU and
GABA ratios (r = −0.405, p = 0.280; data not shown). In
addition, similar to our study, administration of modafinil to
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promote wakefulness in rats specifically increased GLU release
in ventromedial and ventrolateral thalamic nuclei while the
release of GABA remained unaffected (Ferraro et al., 1997).
Although the physiological significance of pharmacologically
induced alterations in wake and sleep states has to be interpreted
with caution, the present and previous data indicate that merely
altering the balance between GLU and GABA may be sufficient
to switch the system between wakefulness and sleep. It also
has to be kept in mind that the participants in the present
study were slightly sleep deprived. Future work may address the
question whether differences in homeostatic sleep pressure affect
the rate at which brain GLU levels change at the transition from
waking to sleep.
Similar to GABA, no changes in thalamic GLX were found
at the wake-to-sleep transition. The GLX signal captures the
combination of GLU and glutamine which is the biosynthetic
precursor of both, GLU and GABA. Virtually opposite changes in
GABA and GLU concentrations from waking to sleep may, thus,
obscure potential changes in GLX resulting from a decreased
GLU level. Interestingly, a strong relationship between right
thalamic GLX levels and disturbed sleep was reported in patients
with restless legs syndrome (Allen et al., 2013). In that study,
however, MR spectroscopy and polysomnographic recordings
were not conducted simultaneously such as in the current work.
CONCLUSION
In conclusion, this study provides first experimental evidence in
humans that dynamic metabolic changes can be measured at the
transition from wakefulness to sleep. Because of the relatively
low sample size, the findings should be qualified as preliminary.
Nevertheless, apart from their importance for informing the
search for molecular mechanisms underlying human sleep-
wake regulation, these insights also have implications for the
interpretation of studies using resting state MR spectroscopy as
a diagnostic tool for sleep-wake and neuropsychiatric disorders
(Allen et al., 2013; Moriguchi et al., 2019). Drowsiness and (N2)
sleep likely occur in many individuals undergoing MR scanning
(Tagliazucchi and Laufs, 2014). Given the evidence provided
here, that GLU concentrations differ between wakefulness
and N2 sleep, control for changes in vigilance state will
be required for the careful interpretation of future MR
spectroscopy findings. Moreover, it will be of great interest
to investigate whether levels of GLU are globally decreased
when the awake brain enters sleep or whether this decrease is
restricted to central hubs subserving sleep-wake control such
as the thalamus.
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